Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TSC-200-A0201 |
Trade Name | |
Synonyms | TSC 200-A0201|TSC200-A0201 |
Drug Descriptions |
TSC-200-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the HPV16 E7 antigen presented on HLA-A*02:01, which potentially inhibit growth of HPV16 E7-expressing tumors (Journal for ImmunoTherapy of Cancer 2023;11). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
TSC-200-A0201 | TSC-200-A0201 | 0 | 1 |
TSC-200-A0201 + TSC-201-B0702 | TSC-200-A0201 TSC-201-B0702 | 0 | 1 |
TSC-200-A0201 + TSC-203-A0201 | TSC-200-A0201 TSC-203-A0201 | 0 | 1 |
TSC-200-A0201 + TSC-204-A0101 | TSC-200-A0201 TSC-204-A0101 | 0 | 1 |
TSC-200-A0201 + TSC-204-A0201 | TSC-200-A0201 TSC-204-A0201 | 0 | 1 |
TSC-200-A0201 + TSC-204-C0702 | TSC-200-A0201 TSC-204-C0702 | 0 | 1 |